Science & Technology
Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBD
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AI188776-01A1
Award Ceiling
$314K
Award Floor
$314K
Close Date
Jan 31, 2026
Total Funding
$314K
Expected Awards
1
Posted Date
Aug 13, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AI188776-01A1
Description
SBIR Phase Phase I award: "Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBD" awarded to Biotherapeutics, Inc. in Blacksburg, Virginia. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $314,363. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, HUBZone businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.